AI-powered MRI radiomics significantly improves prediction of treatment response in advanced liver cancer patients.
Key Details
- 1Multicenter study presented at ASCO 2025 focused on advanced hepatocellular carcinoma (HCC).
- 2AI-based radiomics model analyzed MRI data to predict response to atezolizumab and bevacizumab therapy.
- 3Study included 240 patients; training cohort of 161, validation cohort of 79.
- 4Radiomics model achieved AUC of 0.913 (training) and 0.825 (validation); combined with a key MRI feature, AUC increased to 0.951 and 0.835, respectively.
- 5Significant correlation found between radiomic and conventional MRI features for intrahepatic lesions.
Why It Matters
This work demonstrates the power of AI-driven radiomics to personalize cancer treatment planning, improve patient selection for liver cancer therapies, and highlights growing integration of advanced imaging analytics in clinical oncology workflows.
Source
AuntMinnie
Related News
•Radiology Business
AI Triage Cuts CT Report Turnaround for Pulmonary Embolism—Daytime Only
FDA-backed study finds AI triage tools reduce radiology CT report turnaround times for pulmonary embolism during peak hours.
•Cardiovascular Business
AI Uses Mammograms to Predict Women’s Cardiovascular Disease Risk
AI algorithms can analyze mammograms to predict cardiovascular disease risk, expanding the utility of breast imaging.
•Health Imaging
Most FDA-Cleared AI Devices Lack Pre-Approval Safety Data, Study Finds
A new study finds fewer than 30% of FDA-cleared AI medical devices reported key safety or adverse event data before approval.